Swedish Orphan Biovitrum AB (publ)
OTC:SWOBY

Watchlist Manager
Swedish Orphan Biovitrum AB (publ) Logo
Swedish Orphan Biovitrum AB (publ)
OTC:SWOBY
Watchlist
Price: 17.765 USD Market Closed
Market Cap: $12.2B

Net Margin

0.1%
Current
Declining
by 12.3%
vs 3-y average of 12.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0.1%
=
Net Income
kr14m
/
Revenue
kr27.9B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0.1%
=
Net Income
$14m
/
Revenue
kr27.9B

Peer Comparison

Country Company Market Cap Net
Margin
SE
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
117B SEK
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

In line with most companies in Sweden
Percentile
39th
Based on 2 084 companies
39th percentile
0.1%
Low
-5 565 412.8% — -5.3%
Typical Range
-5.3% — 7.5%
High
7.5% — 12 228%
Distribution Statistics
Sweden
Min -5 565 412.8%
30th Percentile -5.3%
Median 3%
70th Percentile 7.5%
Max 12 228%

Swedish Orphan Biovitrum AB (publ)
Glance View

Swedish Orphan Biovitrum AB (publ), often known as Sobi, navigates the intricate world of biopharmaceuticals with a singular focus on developing and delivering innovative treatments for rare diseases. Founded in the heart of Scandinavia, Sobi has crafted a unique niche by addressing medical needs that are often overlooked by larger pharmaceutical companies. The company specializes in hematology and immunology, focusing on conditions where it can leverage its expertise to make a tangible difference. With a robust pipeline of biopharmaceutical products, Sobi dedicates itself to research and partnerships that not only drive scientific advancements but also ensure that its therapies reach the global market. This mission aligns with its deep commitment to patients whose conditions lack effective treatments. Sobi’s business model thrives on a blend of strategic acquisitions, rigorous clinical development, and expansive distribution capabilities. By acquiring promising therapies and collaborating with other innovators in the biotech space, it continually expands its product portfolio and market reach. Revenue flows primarily from the sales of these specialized therapies, which command premium pricing due to their targeted nature and the complex manufacturing processes involved. The company also invests significantly in its research and development programs, channeling insights from its interactions with healthcare professionals and patients to optimize its offerings. Through its relentless focus on rare diseases, Sobi not only secures financial returns but also significantly impacts the quality of life for patients, staying true to its foundational ethos.

SWOBY Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
0.1%
=
Net Income
kr14m
/
Revenue
kr27.9B
What is Swedish Orphan Biovitrum AB (publ)'s current Net Margin?

The current Net Margin for Swedish Orphan Biovitrum AB (publ) is 0.1%, which is below its 3-year median of 12.4%.

How has Net Margin changed over time?

Over the last 3 years, Swedish Orphan Biovitrum AB (publ)’s Net Margin has decreased from 14.1% to 0.1%. During this period, it reached a low of 0.1% on Sep 30, 2025 and a high of 16.6% on Mar 31, 2023.

Back to Top